Metabolic · Peptide combination (once-weekly injection)

CagriSema

CagriSema is Novo Nordisk's once-weekly combination of cagrilintide (an amylin analogue) and semaglutide. It produced 20.4% weight loss in REDEFINE 1, was submitted to the FDA in December 2025, and missed non-inferiority against tirzepatide in REDEFINE 4.

Not yet approvedSubmitted to the FDA in December 2025 for weight management; decision expected in late 2026 (company-reported)

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperNovo Nordisk · Novo Nordisk pipeline
Drug typePeptide combination (once-weekly injection)
TargetAmylin receptors and GLP-1 receptor
MechanismCombines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist, to reduce appetite through two hormone pathways
Other namescagrilintide/semaglutide, cagrilintide 2.4 mg + semaglutide 2.4 mg

Key points

  • CagriSema pairs semaglutide (the active ingredient in Wegovy and Ozempic) with cagrilintide, a long-acting analogue of the hormone amylin.
  • In the 3,417-participant REDEFINE 1 trial, body weight fell 20.4% at 68 weeks, versus 3.0% with placebo.
  • In REDEFINE 2, in people with type 2 diabetes, weight fell 13.7% versus 3.4% with placebo.
  • In the head-to-head REDEFINE 4 trial, CagriSema did not meet its primary endpoint of non-inferiority to tirzepatide: 23.0% versus 25.5% weight loss at 84 weeks among adherent participants (company-reported).
  • Novo Nordisk submitted CagriSema to the FDA in December 2025 and anticipates a decision by late 2026 (company-reported). openFDA lists no approval record.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Obesity and overweight
Submitted December 2025 based on REDEFINE 1 and 2; FDA decision anticipated late 2026 (company-reported).
Submitted to FDA (company-reported)20
9 active · 10 completed · 1 stopped
90.6% eventual approval
Application → approval: 90.6%
Type 2 diabetes
REIMAGINE Phase 3 program in type 2 diabetes. REIMAGINE 4 showed non-inferiority to tirzepatide on weight but not on HbA1c (company-reported).
Phase 311
2 active · 8 completed · 1 stopped
52.4% eventual approval
Phase 3 → application: 57.8%
Cardiovascular and other indications
REDEFINE 3 cardiovascular outcomes trial (7,101 participants) is active, not recruiting (registry).
Phase 32
1 active · 1 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What CagriSema is

CagriSema is a once-weekly injection from Novo Nordisk that combines two drugs:

Component What it is Role
Semaglutide 2.4 mg GLP-1 receptor agonist, the active ingredient in Wegovy and Ozempic Reduces appetite and slows stomach emptying
Cagrilintide 2.4 mg Long-acting analogue of amylin, a hormone released with insulin after meals Adds a separate satiety signal

The idea is that acting on two appetite pathways at once produces more weight loss than either drug alone. Novo Nordisk is also developing cagrilintide on its own, in a separate program called RENEW, which is not covered by this profile.

Clinical evidence

REDEFINE 1: obesity without diabetes

REDEFINE 1 randomized 3,417 adults with overweight or obesity to CagriSema, semaglutide alone, cagrilintide alone, or placebo. Published in the New England Journal of Medicine in 2025:

  • Body weight changed by −20.4% with CagriSema and −3.0% with placebo at 68 weeks, a difference of −17.3 percentage points.
  • More participants on CagriSema reached weight-loss thresholds of 5%, 20%, 25%, and 30%.
  • Gastrointestinal adverse events affected 79.6% of the CagriSema group and 39.9% of the placebo group. They were mainly transient and mild to moderate.

REDEFINE 2: obesity with type 2 diabetes

In 1,206 people with overweight or obesity and type 2 diabetes, weight fell 13.7% with CagriSema and 3.4% with placebo at 68 weeks. Of those on CagriSema, 73.5% reached an HbA1c of 6.5% or lower, compared with 15.9% on placebo. Gastrointestinal events occurred in 72.5% versus 34.4%.

REDEFINE 4: head-to-head against tirzepatide

In February 2026, Novo Nordisk reported that REDEFINE 4, an open-label, 84-week head-to-head trial, did not meet its primary endpoint of showing that CagriSema was non-inferior to tirzepatide 15 mg for weight loss (company-reported):

Analysis CagriSema 2.4/2.4 mg Tirzepatide 15 mg
If all participants adhered to treatment −23.0% −25.5%
Regardless of adherence (treatment-regimen estimand) −20.2% −23.6%

Other results

In its August 2026 report, Novo Nordisk said REDEFINE 9, testing lower doses, achieved superior weight loss versus placebo. It also said REIMAGINE 4, in type 2 diabetes, showed CagriSema was non-inferior to tirzepatide for weight reduction but not for HbA1c reduction (company-reported).

Scientific perspective

CagriSema clearly produces large weight loss compared with placebo. REDEFINE 1 also included semaglutide-alone and cagrilintide-alone groups for comparison. The commercial and clinical question is comparative. Tirzepatide is already approved and widely used, and in REDEFINE 4 CagriSema could not demonstrate that it was at least as effective. The two estimands in the table above illustrate why trial reports often show two numbers: one asks what the drug can do when taken as directed, the other what happens in practice, including people who stop or switch. See What Is Statistical Significance in Clinical Trials?

Development perspective

  • Regulatory status: not FDA-approved. openFDA lists no application record. Novo Nordisk reports a U.S. submission in December 2025 and anticipated an FDA decision by late 2026 (company-reported).
  • Historical benchmark: about 90.6% of applications that reach the FDA have eventually been approved, often after resubmission. That figure is industry-wide and is not a prediction for CagriSema.
  • Cardiovascular outcomes: REDEFINE 3, with 7,101 participants, has an estimated primary completion in September 2027 (registry).
  • Pipeline changes: two CagriSema trials of new formulations are listed as withdrawn "due to strategic reasons" (registry), and a higher-dose trial is expected to read out in the first half of 2028 (company-reported).

Competitive context

CagriSema would compete with tirzepatide (Zepbound), semaglutide (Wegovy), and Lilly's oral orforglipron (Foundayo), with retatrutide expected to be filed in 2027. Its differentiator is the amylin mechanism. Its challenge, after REDEFINE 4, is showing a clinical reason to choose it over the established leader.

Development timeline

  1. Nov 1, 2022REDEFINE 1 Phase 3 trial begins. Registry
  2. Mar 1, 2023REDEFINE 3 cardiovascular outcomes trial begins. Registry
  3. Jun 22, 2025REDEFINE 1 and REDEFINE 2 published: weight loss of 20.4% and 13.7% at 68 weeks, versus 3.0% and 3.4% with placebo. Peer-reviewed
  4. Dec 2025CagriSema submitted to the U.S. FDA for weight management. Company-reported
  5. Feb 23, 2026Novo Nordisk reports REDEFINE 4 did not meet its primary endpoint of non-inferiority to tirzepatide on weight loss. Company-reported
  6. Aug 4, 2026Novo Nordisk reports REDEFINE 9 (lower doses) achieved superior weight loss versus placebo, and REIMAGINE 4 showed non-inferiority to tirzepatide on weight but not HbA1c. Company-reported

What could change the outlook

  • The FDA decision on the weight-management application, which Novo Nordisk expected by late 2026.
  • How the label and market positioning reflect the REDEFINE 4 result against tirzepatide.
  • The REDEFINE 3 cardiovascular outcomes result (registry estimates primary completion in September 2027).
  • The higher-dose CagriSema trial, which Novo Nordisk expects to read out in the first half of 2028 (company-reported).
  • Gastrointestinal tolerability, reported in about 80% of REDEFINE 1 participants on CagriSema.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention CagriSema. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedNov 4, 2026

    Financial report for the period 1 January 2026 to 30 September 2026

    Pipeline progress • Within obesity, CagriSema (1.0/1.0 mg) delivered encouraging weight loss of 21% at week 68 in the REDEFINE 9 trial. • Also in obesity, the AMAZE 9 phase 3 trial with oral zenagamtide has been initiated in September. • Within diabetes, CagriSema (1.0/1.0 mg) achieved superior weight loss of 12.4%...

  2. Trial resultsCompany-reportedOct 29, 2026

    Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world

    Novo Nordisk today announced that new data from its obesity portfolio will be presented across 26 abstracts at ObesityWeek ® 2026, taking place November 14–17 in Washington, D.C., US.

  3. Trial resultsCompany-reportedOct 20, 2026

    Novo's CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting

    Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego.

All CagriSema disclosures in Pipeline News

Clinical trials

33 registered trials list CagriSema as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Obesity and overweight

TrialPhaseStatusEnrollmentPrimary completionResults posted
REDEFINE 1 · NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Phase 3Active, not recruiting3,400 (est.)Oct 30, 2024No
NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Phase 3Recruiting2,500 (est.)Feb 23, 2028 (est.)No
REDEFINE · NCT07919405
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Phase 3Not yet recruiting1,408 (est.)Jun 1, 2028 (est.)No
REDEFINE 2 · NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Phase 3Completed1,200Jan 28, 2025No
NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Phase 3Completed809Dec 8, 2025No
NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Phase 3Active, not recruiting609Mar 1, 2027 (est.)No
NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase 3Recruiting460 (est.)Mar 20, 2030 (est.)No
NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Phase 3Active, not recruiting400 (est.)Aug 28, 2028 (est.)No
NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Phase 3Completed331Jan 17, 2025No
REDEFINE 6 · NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Phase 3Completed300Jan 6, 2025No
NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Phase 3Completed300Apr 22, 2026No
NCT07357766
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Why stopped (registry): The study is withdrawn due to strategic reasons.
Phase 3Withdrawn0Nov 29, 2027 (est.)No
8 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06267092
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Phase 1Completed164Apr 7, 2025No
RAMBO · NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Phase 1Recruiting144 (est.)May 3, 2028 (est.)No
RASMUS · NCT07527195
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Phase 1Recruiting100 (est.)Apr 28, 2028 (est.)No
NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Phase 1Active, not recruiting80 (est.)Oct 12, 2027 (est.)No
NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Phase 1Completed62Oct 16, 2024No
NCT04940078
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Phase 1Completed40Jan 19, 2022No
NCT06289504
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Phase 1Completed34Oct 16, 2024No
NCT06716307
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Phase 1Completed18Mar 28, 2025No

Type 2 diabetes

TrialPhaseStatusEnrollmentPrimary completionResults posted
REIMAGINE 2 · NCT06065540
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Phase 3Completed2,734Nov 19, 2025No
NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Phase 3Completed1,024Mar 4, 2026No
REIMAGINE 5 · NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase 3Completed1,023Jun 2, 2026No
REIMAGINE 3 · NCT06323161
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Phase 3Completed274Sep 9, 2025No
NCT07817251
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Phase 3Recruiting210 (est.)Jun 9, 2027 (est.)No
REIMAGINE 1 · NCT06323174
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Phase 3Completed189Oct 1, 2025No
REIMAGINEYOUNG · NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Phase 3Recruiting80 (est.)Sep 7, 2029 (est.)No
NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Phase 2Completed142Jun 26, 2026No
NCT04982575
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Phase 2Completed92Jul 7, 2022Yes
NCT07357740
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Why stopped (registry): The study is withdrawn due to strategic reasons.
Phase 2Withdrawn0Aug 25, 2027 (est.)No
1 Phase 1 or other early-stage study
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06403761
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Phase 1Completed158Dec 28, 2025No

Cardiovascular and other indications

TrialPhaseStatusEnrollmentPrimary completionResults posted
REDEFINE 3 · NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Phase 3Active, not recruiting7,101Sep 1, 2027 (est.)No
NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Phase 2Completed626Sep 24, 2025No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). New England Journal of Medicine. 2025;393(7):635–647.Peer-reviewed
  2. Davies MJ, et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). New England Journal of Medicine. 2025;393(7):648–659.Peer-reviewed
  3. Novo Nordisk A/S. Form 6-K (February 23, 2026): REDEFINE 4 results and regulatory update.Company-reported
  4. Novo Nordisk A/S. Form 6-K, company announcement No 48/2026: financial report for the first six months of 2026 (August 4, 2026).Company-reported
  5. ClinicalTrials.gov. REDEFINE 3 (NCT05669755).Registry
  6. ClinicalTrials.gov. REDEFINE 1 (NCT05567796).Registry
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.